Navigation Links
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
Date:5/23/2013

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM).  Vanda was honored at the TCM's 25th Annual Tech Awards Celebration held in Bethesda, Maryland.  The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in Maryland and the surrounding regions.

"We are deeply honored to receive this recognition from the Tech Council of Maryland," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda.  "We are privileged to work in a region that is supportive of our efforts to develop new treatments designed to improve the lives of others."

In selecting Vanda for this award, the TCM recognized Vanda's commitment to address patient needs and the company's work to develop tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24).  Vanda recently announced positive results in the SET and RESET Phase III efficacy studies for Non-24.  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently no treatment for Non-24 has been approved by the U.S. Food and Drug Administration (FDA).  Vanda is targeting a New Drug Application submission with the FDA for tasimelteon in mid-2013.

About The Tech Council of Maryland  
The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland.  TCM's mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed.  For more information, visit www.techcouncilmd.com.  

About Vanda Pharmaceuticals Inc.  
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.   

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Jim Kelly 
Senior Vice President and Chief Financial Officer 
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
2. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
3. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
4. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
5. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
8. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
10. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
11. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year ... be $394.9 billion. The consequences of rapid innovation and growth are often neglected ... technology, it is every business and individual’s job to give something back to the ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com released ... save an average of 70% when buying medication online from Canadian pharmacies verified ... when purchasing from other countries. The report (chart below) compares U.S. and foreign ...
(Date:4/22/2017)... Juan Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan Capistrano ... recently released a parenting report outlining the need for summer camps to provide physical activities ... The Importance of Physical Activity In Summer Camps , With an increase in specialty camps ...
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary ... that youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright ... people involved in violence in the United States. The study, Trends in ...
Breaking Medicine News(10 mins):